West Virginia

Start Pallas's online intake, which takes about five minutes and covers your health history, goals, and current medications. West Virginia law requires a real-time encounter to establish the provider-patient relationship, so a West Virginia-licensed clinician completes a brief scheduled video visit after your intake and, if a GLP-1 is clinically appropriate, prescribes it. A US-licensed pharmacy then fills and ships the medication to your West Virginia address.

The same online intake and scheduled video visit cover tirzepatide. Your West Virginia-licensed clinician reviews your health history and, if appropriate, can prescribe either compounded tirzepatide — prepared per-patient by a US-licensed pharmacy under FDCA §503A — or FDA-approved Zepbound^® or Mounjaro^® (Eli Lilly), available cash-pay through the same intake. Your clinician decides which option fits you; the two are not interchangeable.

Yes — compounded semaglutide is available to eligible West Virginia residents through licensed telehealth. It is prepared per-patient by US-licensed compounding pharmacies under FDCA §503A, and a West Virginia-licensed clinician must prescribe it based on a documented, patient-specific clinical rationale. Pallas serves West Virginia with free shipping. FDA-approved brand-name options like Wegovy^® and Zepbound^® are also available through the same intake.

Yes, within West Virginia's collaborative-practice framework. West Virginia nurse practitioners prescribe under a written collaborative agreement with a West Virginia-licensed physician, verified with the Board of Nursing — the agreement can be dropped only after three years of documented collaborative practice with board approval (W. Va. Code §30-7-15a; §30-7-15b). Semaglutide and tirzepatide are not controlled substances, so a nurse practitioner practicing within this framework can prescribe them through telehealth. Every Pallas clinician who treats West Virginia patients holds an active West Virginia license.

Several licensed telehealth platforms serve West Virginia. When comparing any of them, check that its clinicians are licensed in West Virginia, that it works with US-licensed §503A compounding pharmacies, and that its LegitScript certification is verifiable in LegitScript's public database. Pallas serves West Virginia residents and is LegitScript Healthcare Merchant Certified.

Yes — West Virginia law requires one live video visit to establish the provider-patient relationship, the real-time encounter the statute requires and prefers in audio-visual form. Your Pallas intake comes first, then a West Virginia-licensed provider completes a brief scheduled video visit; after that first visit, ongoing care — check-ins, messaging, and refills — continues asynchronously.

Yes. Compounded semaglutide prescribed by a West Virginia-licensed provider and dispensed by a licensed compounding pharmacy is legal when prepared for an individual patient with a documented clinical need. Pallas works only with U.S. state-licensed 503A and 503B compounding pharmacies.

West Virginia Medicaid covers GLP-1s for type 2 diabetes with prior authorization. Coverage for weight-management indications is limited. Compounded GLP-1s are not covered. Pallas is a cash-pay service, so Medicaid rules do not apply to our prescriptions.

Most West Virginia patients receive their medication within 2–3 business days of the pharmacy filling the prescription. Charleston, Huntington, Morgantown, and other West Virginia metros typically ship fastest; rural addresses may take an extra day.

Pallas is a cash-pay telehealth service — there is no insurance to bill. Your Pallas Membership covers your clinician's review, ongoing check-ins, and care-team messaging; the medication is billed separately and ships free to your West Virginia address, only when a clinician prescribes it. You see your full price during intake before you pay anything — no surprise renewal markups. The price is the same whether you are in Charleston, Huntington, or a rural West Virginia ZIP code.

Eligibility is always decided by a West Virginia-licensed clinician after reviewing your full intake, never by an automated quiz. In general, GLP-1 medications for weight management are considered for adults with a BMI of 30 or higher, or a BMI of 27 or higher together with a weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea. Your clinician also reviews your medical history and current medications to confirm a GLP-1 is appropriate and safe for you, and will tell you if it is not. If you're already taking a GLP-1, tell your clinician which medication and dose during intake — many patients transfer their care to Pallas and continue at a comparable dose or an adjusted titration plan.

Brand-name medications — Wegovy^® and Ozempic^® (semaglutide) and Zepbound^® and Mounjaro^® (tirzepatide) — are FDA-approved products from their manufacturers, offered cash-pay. Compounded semaglutide and tirzepatide are prepared on a per-patient basis by US-licensed compounding pharmacies, regulated under federal law (FDCA §503A) and by state boards of pharmacy, when a clinician documents a patient-specific clinical need. While these pharmacies are highly regulated, the compounded medications themselves are not FDA-approved, are not generic versions of brand-name drugs, and have not been evaluated by the FDA for safety, efficacy, or quality. Which option fits you is a clinical decision you make with your West Virginia-licensed provider.

Most patients use a once-weekly injection with a very fine needle, but a compounded oral semaglutide tablet is available for people who would rather not inject. Both are prescribed only after a clinician confirms they are appropriate for you, and your provider can help you weigh which form fits your routine and goals.

The most common side effects are gastrointestinal — nausea, constipation, diarrhea, or reflux — and they are usually mildest when the dose is raised slowly, which is why clinicians titrate up gradually. GLP-1s are not right for everyone; they are avoided in people with a personal or family history of medullary thyroid carcinoma or MEN2, and during pregnancy. Your Pallas clinician screens for these before prescribing and stays available to help you manage any side effects.

You complete a detailed online intake in under five minutes, sharing your health history, goals, and current medications. A clinician licensed by the West Virginia Board of Medicine then meets you for a short scheduled video visit — the real-time encounter West Virginia law requires before prescribing — and may follow up by secure message or request labs if your history calls for it. If a GLP-1 is appropriate, your prescription goes to a licensed pharmacy that ships to any West Virginia address, usually within 2–3 business days.

Pallas care is ongoing, not a one-time script. Your plan renews on a regular cadence so your medication arrives before you run out, and your clinician schedules check-ins to monitor your response, adjust your dose, and manage side effects. You can message your care team from the Pallas app or your patient portal, and change your plan or cancel anytime from the portal — no phone calls or retention hoops.

Compounded semaglutide injection through Pallas is $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any West Virginia address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.

Compounded tirzepatide injection through Pallas is $179 first month, then $299 every 4 weeks, charged once a clinician prescribes. Cancel anytime. That one plan price includes your US-licensed provider, ongoing check-ins, dose adjustments, and unlimited care-team messaging — no separate membership fee. Medication ships free to any West Virginia address, only if a clinician prescribes it, and you are refunded in full if a clinician decides treatment isn't right for you.

Yes. FDA-approved Wegovy^® (pen or pill), Zepbound^® and Foundayo^™ for chronic weight management — plus Ozempic^® and Mounjaro^® for type 2 diabetes — are available to West Virginia patients cash-pay: the daily Wegovy^® pill and Foundayo^™ are $299 for your first month, then $499 every 4 weeks, and the weekly pens start at $1,069/mo; insurance is not billed. Whether a brand-name or compounded medication is appropriate for you is determined by a clinician licensed in West Virginia during intake.

Coverage of GLP-1 medications for weight loss through Medicaid is limited. West Virginia Medicaid covers GLP-1s for type 2 diabetes with prior authorization. Coverage for weight-management indications is limited. Compounded GLP-1s are not covered. Pallas is a cash-pay telehealth service — we do not bill Medicaid or private insurance. Pricing is flat and disclosed up front; the cost questions on this page carry current plan terms.

You have two cash-pay paths in West Virginia, and neither requires insurance. One: stay on FDA-approved Wegovy^® or Zepbound^® at flat cash-pay pricing from $1,069/mo. Two: if a clinician licensed in West Virginia determines it is clinically appropriate for you, a compounded semaglutide plan ($139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime.) or compounded tirzepatide plan ($179 first month, then $299 every 4 weeks, charged once a clinician prescribes. Cancel anytime.), prepared per-patient by a US-licensed pharmacy under FDCA §503A. There is no gap in care: start the online intake, tell your clinician what you take now and your current dose, and they factor that history into your treatment plan and starting dose. Our guide to switching GLP-1 telehealth providers on the Pallas blog covers records, timing, and what to expect.

That is a decision you make with your clinician. Semaglutide activates the GLP-1 receptor; tirzepatide activates both the GLP-1 and GIP receptors. In the SURMOUNT-5 head-to-head trial of the FDA-approved products, Zepbound^® (tirzepatide 10 mg or 15 mg weekly) produced greater average weight loss than Wegovy^® (semaglutide 1.7 mg or 2.4 mg weekly) — 20.2% versus 13.7% of body weight over 72 weeks. Wegovy^®'s maximum dose is now 7.2 mg weekly, which was not studied in SURMOUNT-5; in the separate STEP UP trial it reached 18.7% average weight loss over 72 weeks. Clinical trial outcomes for the FDA-approved products have not been established for compounded preparations. Individual results vary. Semaglutide plans cost less and semaglutide has the longer post-market record; a clinician licensed in West Virginia weighs your history, goals, and budget to recommend a starting point.

It depends on what you are comparing. Pallas is a cash-pay telehealth service that serves every ZIP code in West Virginia with one all-in plan price for compounded semaglutide: $139 first month, then $199 every 4 weeks, charged once a clinician prescribes. Cancel anytime. There is no separate membership fee, and nothing is charged until a clinician prescribes. West Virginia requires one live video visit, which is included. Before paying any service, check whether the quoted price includes the medication or is a membership billed on top of it, whether the company is LegitScript-certified, and whether you are charged before a clinician has prescribed. The comparison table on this page quotes other services' published prices as of September 24, 2026.